anidulafungin has been researched along with gilteritinib in 1 studies
| Studies (anidulafungin) | Trials (anidulafungin) | Recent Studies (post-2010) (anidulafungin) | Studies (gilteritinib) | Trials (gilteritinib) | Recent Studies (post-2010) (gilteritinib) |
|---|---|---|---|---|---|
| 568 | 33 | 331 | 135 | 12 | 132 |
| Protein | Taxonomy | anidulafungin (IC50) | gilteritinib (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.76 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.0007 | |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0003 | |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | 0.0035 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0003 | |
| Transcription factor ETV6 | Homo sapiens (human) | 0.0085 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0036 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
1 other study(ies) available for anidulafungin and gilteritinib
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |